

# United States of America

## Tuberculosis profile

Population 2016

322 million

| Estimates of TB burden*, 2016 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 0.53 (0.52–0.53)   | 0.16 (0.16–0.17)              |
| Mortality (HIV+TB only)       | 0.086 (0.057–0.12) | 0.03 (0.02–0.04)              |
| Incidence (includes HIV+TB)   | 10 (8.7–12)        | 3.1 (2.7–3.6)                 |
| Incidence (HIV+TB only)       | 0.56 (0.47–0.65)   | 0.17 (0.15–0.2)               |
| Incidence (MDR/RR-TB)**       | 0.18 (0.13–0.22)   | 0.05 (0.04–0.07)              |

Estimated TB incidence by age and sex (thousands)\*, 2016

|         | 0-14 years       | > 14 years    | Total         |
|---------|------------------|---------------|---------------|
| Females | 0.41 (0.35–0.47) | 3.6 (3.1–4.1) | 4 (3.4–4.6)   |
| Males   | 0.46 (0.39–0.53) | 5.7 (4.8–6.5) | 6.1 (5.2–7.1) |
| Total   | 0.88 (0.74–1)    | 9.3 (7.9–11)  | 10 (8.7–12)   |

TB case notifications, 2016

|  |       |
|--|-------|
| Total cases notified                                   | 9 257 |
| Total new and relapse                                  | 8 814 |
| - % tested with rapid diagnostics at time of diagnosis |       |
| - % with known HIV status                              | 93%   |
| - % pulmonary  | 79%   |
| - % bacteriologically confirmed among pulmonary        | 84%   |

Universal health coverage and social protection

|  |                  |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2016             | 87% (75–100)     |
| TB patients facing catastrophic total costs                            |                  |
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 | 0.06 (0.05–0.07) |

TB/HIV care in new and relapse TB patients, 2016

|   | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | 466    | 6%  |
| - on antiretroviral therapy                         |        |     |

| Drug-resistant TB care, 2016                                | New cases      | Previously treated cases  | Total number*** |
|---|----------------|---------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |                |                           | 130 (100–150)   |
| Estimated % of TB cases with MDR/RR-TB                      | 1.5% (1.2–1.8) | 5.6% (3.2–9.1)            |                 |
| % notified tested for rifampicin resistance                 | 75%            | 67%                       | 6 949           |
| MDR/RR-TB cases tested for resistance to second-line drugs  |                |                           | 94              |
| Laboratory-confirmed cases                                  |                | MDR/RR-TB: 113, XDR-TB: 1 |                 |
| Patients started on treatment ****                          |                | MDR/RR-TB: 113, XDR-TB: 1 |                 |

| Treatment success rate and cohort size                          | Success | Cohort |
|---|---------|--------|
| New and relapse cases registered in 2015                        | 83%     | 8 953  |
| Previously treated cases, excluding relapse, registered in 2015 | 77%     | 465    |
| HIV-positive TB cases registered in 2015                        | 77%     | 429    |
| MDR/RR-TB cases started on second-line treatment in 2014        | 78%     | 108    |
| XDR-TB cases started on second-line treatment in 2014           | 0%      | 2      |

TB preventive treatment, 2016

|   |  |
|---|--|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   |  |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment |  |

TB financing, 2017

|                                    |     |
|------------------------------------|-----|
| National TB budget (US\$ millions) | 142 |
|------------------------------------|-----|


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB